Literature DB >> 17017533

Clinical and pathologic features of families with LRRK2-associated Parkinson's disease.

N R Whaley1, R J Uitti, D W Dickson, M J Farrer, Z K Wszolek.   

Abstract

The etiology for Parkinson's disease (PD) remains unknown. Genetic causes have been identified with several distinct mutations. Recently, 9 mutations involving a novel gene, leucine-rich repeat kinase 2 (LRRK2), have been identified as the cause of autosomal dominant PD in kindreds, with some of them previously linked to the PARK8 locus on chromosome 12. LRRK2 mutations are relatively common genetic causes of familial and sporadic PD. In addition, these mutations have been identified in diverse populations. The clinical and pathologic features of LRRK2-associated PD are indistinguishable from idiopathic PD; however, considerable clinical and pathologic variability exists even among kindreds. This short review highlights the clinical and pathologic features in LRRK2-associated parkinsonism.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17017533     DOI: 10.1007/978-3-211-45295-0_34

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  14 in total

1.  Wild-type LRRK2 but not its mutant attenuates stress-induced cell death via ERK pathway.

Authors:  Anthony K F Liou; Rehana K Leak; Lihua Li; Michael J Zigmond
Journal:  Neurobiol Dis       Date:  2008-07-08       Impact factor: 5.996

2.  Medical management of Parkinson's disease.

Authors:  Marvin M Goldenberg
Journal:  P T       Date:  2008-10

Review 3.  Evolution of neurodegeneration.

Authors:  Mark R Cookson
Journal:  Curr Biol       Date:  2012-09-11       Impact factor: 10.834

4.  Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice.

Authors:  H L Melrose; J C Dächsel; B Behrouz; S J Lincoln; M Yue; K M Hinkle; C B Kent; E Korvatska; J P Taylor; L Witten; Y-Q Liang; J E Beevers; M Boules; B N Dugger; V A Serna; A Gaukhman; X Yu; M Castanedes-Casey; A T Braithwaite; S Ogholikhan; N Yu; D Bass; G Tyndall; G D Schellenberg; D W Dickson; C Janus; M J Farrer
Journal:  Neurobiol Dis       Date:  2010-07-24       Impact factor: 5.996

5.  Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study.

Authors:  Daniel G Healy; Mario Falchi; Sean S O'Sullivan; Vincenzo Bonifati; Alexandra Durr; Susan Bressman; Alexis Brice; Jan Aasly; Cyrus P Zabetian; Stefano Goldwurm; Joaquim J Ferreira; Eduardo Tolosa; Denise M Kay; Christine Klein; David R Williams; Connie Marras; Anthony E Lang; Zbigniew K Wszolek; Jose Berciano; Anthony H V Schapira; Timothy Lynch; Kailash P Bhatia; Thomas Gasser; Andrew J Lees; Nicholas W Wood
Journal:  Lancet Neurol       Date:  2008-06-06       Impact factor: 44.182

Review 6.  The role of anti-inflammatory agents in Parkinson's disease.

Authors:  Edith G McGeer; Patrick L McGeer
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

7.  A genome-wide scan in an Amish pedigree with parkinsonism.

Authors:  S L Lee; D G Murdock; J L McCauley; Y Bradford; A Crunk; L McFarland; L Jiang; T Wang; N Schnetz-Boutaud; J L Haines
Journal:  Ann Hum Genet       Date:  2008-05-21       Impact factor: 1.670

8.  Leucine-rich repeat kinase 2 regulates Sec16A at ER exit sites to allow ER-Golgi export.

Authors:  Hyun Jin Cho; Jia Yu; Chengsong Xie; Parvathi Rudrabhatla; Xi Chen; Junbing Wu; Loukia Parisiadou; Guoxiang Liu; Lixin Sun; Bo Ma; Jinhui Ding; Zhihua Liu; Huaibin Cai
Journal:  EMBO J       Date:  2014-09-08       Impact factor: 11.598

9.  The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation.

Authors:  Elisa Greggio; Ibardo Zambrano; Alice Kaganovich; Alexandra Beilina; Jean-Marc Taymans; Veronique Daniëls; Patrick Lewis; Shushant Jain; Jinhui Ding; Ali Syed; Kelly J Thomas; Veerle Baekelandt; Mark R Cookson
Journal:  J Biol Chem       Date:  2008-04-08       Impact factor: 5.157

10.  Conserved role of dopamine in the modulation of behavior.

Authors:  Andrés G Vidal-Gadea; Jonathan T Pierce-Shimomura
Journal:  Commun Integr Biol       Date:  2012-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.